Weight care

GLP-1 weight loss, prescribed only if it is right for you

Medical review pending · Last updated 2026-11-03

GLP-1 medicines have changed how clinicians treat obesity. Metabcore plans to connect you with licensed providers who can evaluate you for FDA-approved options and support you over time.

What is a GLP-1 medicine?

GLP-1 receptor agonists mimic a natural gut hormone that helps regulate appetite and blood sugar. They slow stomach emptying and act on appetite signals in the brain, which can help people eat less. They are used alongside a reduced-calorie diet and increased physical activity.

FDA-approved options a provider may consider

Semaglutide (Wegovy®)

Weekly injection or daily tablet. GLP-1 receptor agonist.

Semaglutide overview →

Tirzepatide (Zepbound®)

Weekly injection. Dual GLP-1 and GIP receptor agonist.

Tirzepatide overview →

Orforglipron (Foundayo™)

Once-daily oral GLP-1, FDA-approved in 2026 for chronic weight management.

Page coming soon

Brand names are trademarks of their owners and are used only to identify FDA-approved products. Availability and pricing depend on your provider, pharmacy, and the manufacturer's programs.

Why we do not advertise compounded GLP-1s

During the 2022–2025 shortages, pharmacies were allowed to compound semaglutide and tirzepatide. FDA has since declared those shortages resolved, issued dozens of warning letters to online sellers, and in April 2026 proposed excluding these drugs from the outsourcing-facility bulks list. Compounded drugs are not FDA-approved. Our program is built around FDA-approved medicines.

Is it right for me?

GLP-1s are not appropriate for everyone, including people with a personal or family history of medullary thyroid carcinoma or MEN 2, a history of pancreatitis (discuss with your provider), or who are pregnant. Compare: tirzepatide vs. semaglutide · Zepbound vs. Wegovy.

Important safety information: GLP-1 medicines

This is a summary, not the full prescribing information. Always read the FDA-approved Medication Guide and talk with your prescriber. Full labels: Wegovy® · Zepbound®.

Boxed warning, thyroid C-cell tumors: In rodents, semaglutide and tirzepatide caused thyroid C-cell tumors. It is unknown whether they cause these tumors, including medullary thyroid carcinoma (MTC), in humans. Do not use if you or a family member have had MTC or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Serious side effects can include: inflammation of the pancreas (pancreatitis), gallbladder problems, low blood sugar (especially with insulin or sulfonylureas), kidney problems from dehydration, severe stomach and intestinal side effects, serious allergic reactions, diabetic retinopathy complications (in people with type 2 diabetes), and, with Wegovy®, increased heart rate. Seek care right away for severe stomach pain, signs of an allergic reaction, or a lump or swelling in the neck.
Common side effects: nausea, vomiting, diarrhea, constipation, stomach pain, and decreased appetite.
Anesthesia: Tell your provider before any planned surgery or procedure requiring anesthesia or deep sedation; these medicines can raise the risk of food or liquid getting into the lungs.
Pregnancy: Not for use during pregnancy. Tell your provider if you are pregnant, planning pregnancy, or breastfeeding. Tirzepatide may reduce the effectiveness of oral birth control.
Tell your provider about all medicines you take, including other GLP-1 medicines.

Prescription eligibility is determined only by a licensed clinician. Draft ISI for medical and legal review; replace with partner-approved, product-specific ISI before launch.

Frequently asked questions

Who may qualify for GLP-1 weight-loss medicine?

FDA-approved weight-management GLP-1s are labeled for adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. A licensed provider makes the final decision after reviewing your history.

Do you offer compounded semaglutide or tirzepatide?

No. FDA has declared the national shortages of semaglutide and tirzepatide resolved and has restricted compounded copies. Our program features FDA-approved medicines only.

How much weight will I lose?

No one can promise a specific result. In clinical trials, average weight loss varied by medicine and dose, and individual results ranged widely. Your provider can discuss realistic expectations.

Sources

Sources are listed for reference and do not imply endorsement. Regulatory status can change; check the date above.